MTOR and cancer: On the contrary, contributing factors of CSCs, especially in cancer management, are their “bad” functions including treatment resistance, recurrence, and metastasis; usually their activation of different signaling pathways such as Notch, Wnt/β-catenin, PI3K/Akt/mTOR, JAK/STAT, and HH signaling pathways [33].